接口服务接入指南

基础设定

数据服务地址

https://srv-openapi.bcpmdata.com

HTTP请求设定

HTTP请求方式 固定为 POST

Content-Type: application/json

Authorization: Bearer <你的token>

HTTP响应设定

接口响应 的 HTTP状态码， 固定为200。请使用‘code’参数值，做业务判断

业务状态码示例

接口限流设定

全部数据接口，限制 1次/s 调用频率

认证接口

/user/v1/auth/jwt

curl --location --request POST 'https://srv-openapi.bcpmdata.com/user/v1/auth/jwt' \
--header 'Content-Type: application/json' \
--data-raw '{
    "app_id": "你的app_id",
    "secret": "你的secret"
}'

{
    "code": 10200,
    "data": {
        "token": "eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJhcHBfaWQiOiJ0ZXN0MTIzNDU2Nzg5MDEyIiwiZXhwIjoxNzQxODA0MjU5LCJpYXQiOjE3NDE4MDA2NTl9.mA8JlNs-r-XD9czRt73y7m-RVunLaTEjYHDNQ4etjZs"
    },
    "message": ""
}

数据接口

政策法规数据库

/pharma/demo/v1/policies_regulations/list

*样例数据限制条件：release_date（发布日期）=2025-01-01至2025-04-30

curl --location --request POST 'https://srv-openapi.bcpmdata.com/pharma/demo/v1/policies_regulations/list' \
--header 'Content-Type: application/json' \
--header 'Authorization: Bearer 你的token' \
--data-raw '{
    "search": {
        "all": "关于",
        "title": "关于",
        "number": "2025",
        "release_department": "国家",
        "start_date": {
            "min": "2025-01-01",
            "max": "2035-11-11"
        },
        "release_date": {
            "min": "2025-01-01",
            "max": "2025-04-30"
        }
    },
    "sort_flag": "zone",
    "sort_desc": true,
    "page": 1,
    "page_size": 10
}'

{
    "code": 10200,
    "data": {
        "list": [
            {
                "title": "国家药监局药审中心关于发布<抗hiv感染药物临床耐药性研究及数据递交指导原则>的通告(2025年第23号)",
                "number": "2025年第23号",
                "release_date": "2025-07-02",
                "start_date": "",
                "release_department": [
                    "国家药品监督管理局",
                    "国家药品审评中心（CDE"
                ],
                "type": "指导原则",
                "validity_period": "现行有效",
                "zone": "中国",
                "abstract": "为指导抗HIV感染药物临床耐药性研究、数据递交及其评价，提供可供参考的技术标准，药审中心制定了《抗HIV感染药物临床耐药性研究及数据递交指导原则》（见附件）。根据《国家药监局综合司关于印发药品技术指导原则发布程序的通知》（药监综药管〔2020〕9号）要求，经国家药品监督管理局审查同意，现予发布，自发布之日起施行。\n特此通告。\n附件：抗HIV感染药物临床耐药性研究及数据递交指导原则\n国家药监局药审中心\n2025年6月5日\n相关附件\n序号附件名称1抗HIV感染药物临床耐药性研究及数据递交指导原则.pdf\n>",
                "enclosure": [
                    {
                        "name": "抗HIV感染药物临床耐药性研究及数据递交指导原则.pdf",
                        "path": "https://pharma.bcpmdata.com/download?oss=NB2HI4DTHIXS66LBN5ZG63THPF2W4LLFNZ2GK4TQOJUXGZJNMRQXIYJON5ZXGLLDNYWXG2DBNZTWQYLJFZQWY2LZOVXGG4ZOMNXW2L3QN5WGSY3JMVZS6ZDPMN2W2ZLOOQXTEOBRGE4GIZRUMM4GCOBZGA4WCYJSHE3TOZJUMI4DCZLEGQYTQYJOOBSGM---&alias_id=db1c7b98ef"
                    }
                ]
            }
        ],
        "total": 7
    },
    "message": ""
}

疾病知识库数据库

/ebm/demo/v1/disease/list

*样例数据限制条件：disease_categories_anatomical（解剖学分类）=内分泌疾病

curl --location --request POST 'https://srv-openapi.bcpmdata.com/ebm/demo/v1/disease/list' \
--header 'Content-Type: application/json' \
--header 'Authorization: Bearer 你的token' \
--data '{
    "search": {
    "disease_name_cn": "高胆固醇血症",
        "disease_name": "Familial",
        "aliases": [
            "Familial"
        ],
        "aliases_cn": [
            "高胆固醇血症"
        ],
        "omim_code": "143890",
        "mesh_code": "D006938"
    },
    "page": 1,
    "page_size": 10
}'

{
    "code": 10200,
    "data": {
        "list": [
            {
                "object_id": "",
                "key_id": "819171e5f1f998f1500bad6fca274ec1",
                "disease_name": "Hypoalphalipoproteinemia",
                "disease_name_cn": "低α脂蛋白血症",
                "aliases": [
                    "Hypoalphalipoproteinemia"
                ],
                "aliases_cn": [
                    "低α脂蛋白血症"
                ],
                "disease_categories_global": [
                    {
                        "en": "Metabolic diseases",
                        "cn": "代谢性疾病"
                    },
                    {
                        "en": "Rare diseases",
                        "cn": "罕见病"
                    },
                    {
                        "en": "Genetic diseases",
                        "cn": "遗传病"
                    }
                ],
                "disease_categories_anatomical": [
                    {
                        "en": "Endocrine diseases",
                        "cn": "内分泌疾病"
                    },
                    {
                        "en": "Cardiovascular diseases",
                        "cn": "心血管疾病"
                    },
                    {
                        "en": "Blood diseases",
                        "cn": "血液疾病"
                    }
                ],
                "omim_code": "",
                "mesh_code": "",
                "do_code": [],
                "icd11_code": [],
                "icd10_code": [],
                "icd9cm_code": "",
                "snomed_ct_code": [],
                "umls_code": [],
                "summary_omim": {
                    "en": "",
                    "cn": ""
                },
                "summary_gard": {
                    "en": "",
                    "cn": ""
                },
                "summary_do": {
                    "en": "",
                    "cn": ""
                },
                "summary_uniprot": {
                    "en": "",
                    "cn": ""
                },
                "summary_malacards": {
                    "en": "Hypoalphalipoproteinemia is related to hypoalphalipoproteinemia, primary, 2, intermediate and hypoalphalipoproteinemia, primary, 2. An important gene associated with Hypoalphalipoproteinemia is APOA1 (Apolipoprotein A1), and among its related pathways/superpathways are Metabolism and Transport of inorganic cations/anions and amino acids/oligopeptides. The drugs Nicotinamide and Folic acid have been mentioned in the context of this disorder. Affiliated tissues include endothelial and heart, and related phenotypes are Increased free cholesterol and Increased LDL uptake",
                    "cn": "低α脂蛋白血症与低α脂蛋白血症有关，原发性，2，中度和低α脂蛋白血症，原发性，2。与低α脂蛋白血症相关的一个重要基因是APOA1（载脂蛋白A1），其相关途径/超途径包括无机阳离子/阴离子和氨基酸/寡肽的代谢和转运。在这种疾病的背景下已经提到了药物烟酰胺和叶酸。附属组织包括内皮和心脏，相关表型是游离胆固醇增加和低密度脂蛋白摄取增加"
                },
                "summary_medlineplus": {
                    "en": "",
                    "cn": ""
                },
                "related_genes_or_enhancers": [
                    {
                        "symbol": "APOA1",
                        "description": "Apolipoprotein A1",
                        "category": "Protein Coding",
                        "protein_names": [
                            {
                                "protein_names": "Apolipoprotein A-I,Apolipoprotein A1",
                                "function": "Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility",
                                "pubmed_ids": [
                                    "1909888"
                                ]
                            }
                        ]
                    },
                    {
                        "symbol": "ABCA1",
                        "description": "ATP Binding Cassette Subfamily A Member 1",
                        "category": "Protein Coding",
                        "protein_names": [
                            {
                                "protein_names": "Phospholipid-transporting ATPase ABCA1,7.6.2.1ATP-binding cassette sub-family A member 1,ATP-binding cassette transporter 1,Cholesterol efflux regulatory protein",
                                "function": "Catalyzes the translocation of specific phospholipids from the cytoplasmic to the extracellular/lumenal leaflet of membrane coupled to the hydrolysis of ATP (PubMed:24097981). Thereby, participates in phospholipid transfer to apoliproteins to form nascent high density lipoproteins/HDLs (PubMed:14754908). Transports preferentially phosphatidylcholine over phosphatidylserine (PubMed:24097981). May play a similar role in the efflux of intracellular cholesterol to apoliproteins and the formation of nascent high density lipoproteins/HDLs (PubMed:10533863, PubMed:14754908, PubMed:24097981)",
                                "pubmed_ids": [
                                    "10533863",
                                    "14754908",
                                    "24097981"
                                ]
                            }
                        ]
                    },
                    {
                        "symbol": "LCAT",
                        "description": "Lecithin-Cholesterol Acyltransferase",
                        "category": "Protein Coding",
                        "protein_names": [
                            {
                                "protein_names": "Phosphatidylcholine-sterol acyltransferase,2.3.1.431-alkyl-2-acetylglycerophosphocholine esterase,Lecithin-cholesterol acyltransferase,Phospholipid-cholesterol acyltransferase,Platelet-activating factor acetylhydrolase",
                                "function": "Central enzyme in the extracellular metabolism of plasma lipoproteins. Synthesized mainly in the liver and secreted into plasma where it converts cholesterol and phosphatidylcholines (lecithins) to cholesteryl esters and lysophosphatidylcholines on the surface of high and low density lipoproteins (HDLs and LDLs) (PubMed:10329423, PubMed:19065001, PubMed:26195816). The cholesterol ester is then transported back to the liver. Has a preference for plasma 16:0-18:2 or 18:O-18:2 phosphatidylcholines (PubMed:8820107). Also produced in the brain by primary astrocytes, and esterifies free cholesterol on nascent APOE-containing lipoproteins secreted from glia and influences cerebral spinal fluid (CSF) APOE- and APOA1 levels. Together with APOE and the cholesterol transporter ABCA1, plays a key role in the maturation of glial-derived, nascent lipoproteins. Required for remodeling high-density lipoprotein particles into their spherical forms (PubMed:10722751). Catalyzes the hydrolysis of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor or PAF) to 1-O-alkyl-sn-glycero-3-phosphocholine (lyso-PAF) (PubMed:8016111). Also catalyzes the transfer of the acetate group from PAF to 1-hexadecanoyl-sn-glycero-3-phosphocholine forming lyso-PAF (PubMed:8016111). Catalyzes the esterification of (24S)-hydroxycholesterol (24(S)OH-C), also known as cerebrosterol to produce 24(S)OH-C monoesters (PubMed:24620755)",
                                "pubmed_ids": [
                                    "10329423",
                                    "10722751"
                                ]
                            }
                        ]
                    },
                    {
                        "symbol": "APOA2",
                        "description": "Apolipoprotein A2",
                        "category": "Protein Coding",
                        "protein_names": [
                            {
                                "protein_names": "Apolipoprotein A-II,Apolipoprotein A2",
                                "function": "May stabilize HDL (high density lipoprotein) structure by its association with lipids, and affect the HDL metabolism",
                                "pubmed_ids": []
                            }
                        ]
                    },
                    {
                        "symbol": "LIPC",
                        "description": "Lipase C, Hepatic Type",
                        "category": "Protein Coding",
                        "protein_names": [
                            {
                                "protein_names": "Hepatic triacylglycerol lipase,3.1.1.3Lipase member C,Lysophospholipase,Phospholipase A1",
                                "function": "Catalyzes the hydrolysis of triglycerides and phospholipids present in circulating plasma lipoproteins, including chylomicrons, intermediate density lipoproteins (IDL), low density lipoproteins (LDL) of large size and high density lipoproteins (HDL), releasing free fatty acids (FFA) and smaller lipoprotein particles (PubMed:7592706, PubMed:8798474, PubMed:12032167, PubMed:26193433). Also exhibits lysophospholipase activity (By similarity). Can hydrolyze both neutral lipid and phospholipid substrates but shows a greater binding affinity for neutral lipid substrates than phospholipid substrates (By similarity). In native LDL, preferentially hydrolyzes the phosphatidylcholine species containing polyunsaturated fatty acids at sn-2 position (PubMed:26193433)",
                                "pubmed_ids": [
                                    "12032167",
                                    "26193433"
                                ]
                            }
                        ]
                    },
                    {
                        "symbol": "LPL",
                        "description": "Lipoprotein Lipase",
                        "category": "Protein Coding",
                        "protein_names": [
                            {
                                "protein_names": "Lipoprotein lipase,3.1.1.34Phospholipase A1",
                                "function": "Key enzyme in triglyceride metabolism. Catalyzes the hydrolysis of triglycerides from circulating chylomicrons and very low density lipoproteins (VLDL), and thereby plays an important role in lipid clearance from the blood stream, lipid utilization and storage (PubMed:8675619, PubMed:11342582, PubMed:27578112). Although it has both phospholipase and triglyceride lipase activities it is primarily a triglyceride lipase with low but detectable phospholipase activity (PubMed:7592706, PubMed:12032167). Mediates margination of triglyceride-rich lipoprotein particles in capillaries (PubMed:24726386). Recruited to its site of action on the luminal surface of vascular endothelium by binding to GPIHBP1 and cell surface heparan sulfate proteoglycans (PubMed:11342582, PubMed:27811232)",
                                "pubmed_ids": [
                                    "11342582",
                                    "12032167"
                                ]
                            }
                        ]
                    },
                    {
                        "symbol": "PLTP",
                        "description": "Phospholipid Transfer Protein",
                        "category": "Protein Coding",
                        "protein_names": [
                            {
                                "protein_names": "Phospholipid transfer protein,Lipid transfer protein II",
                                "function": "Mediates the transfer of phospholipids and free cholesterol from triglyceride-rich lipoproteins (low density lipoproteins or LDL and very low density lipoproteins or VLDL) into high-density lipoproteins (HDL) as well as the exchange of phospholipids between triglyceride-rich lipoproteins themselves (PubMed:7654777, PubMed:9132017, PubMed:11013307, PubMed:19321130, PubMed:21515415, PubMed:29883800). Facilitates the transfer of a spectrum of different lipid molecules, including diacylglycerol, phosphatidic acid, sphingomyelin, phosphatidylcholine, phosphatidylinositol, phosphatidylglycerol, cerebroside and phosphatidyl ethanolamine (PubMed:9132017). Plays an important role in HDL remodeling which involves modulating the size and composition of HDL (PubMed:29883800). Also plays a key role in the uptake of cholesterol from peripheral cells and tissues that is subsequently transported to the liver for degradation and excretion (PubMed:21736953). Two distinct forms of PLTP exist in plasma: an active form that can transfer phosphatidylcholine from phospholipid vesicles to HDL, and an inactive form that lacks this capability (PubMed:11013307)",
                                "pubmed_ids": [
                                    "11013307",
                                    "19321130"
                                ]
                            }
                        ]
                    },
                    {
                        "symbol": "HDLCQ14",
                        "description": "Hypoalphalipoproteinemia, Primary",
                        "category": "Genetic Locus",
                        "protein_names": []
                    },
                    {
                        "symbol": "CETP",
                        "description": "Cholesteryl Ester Transfer Protein",
                        "category": "Protein Coding",
                        "protein_names": [
                            {
                                "protein_names": "Cholesteryl ester transfer protein,Lipid transfer protein I",
                                "function": "Involved in the transfer of neutral lipids, including cholesteryl ester and triglyceride, among lipoprotein particles. Allows the net movement of cholesteryl ester from high density lipoproteins/HDL to triglyceride-rich very low density lipoproteins/VLDL, and the equimolar transport of triglyceride from VLDL to HDL (PubMed:3600759, PubMed:24293641, PubMed:3281933). Regulates the reverse cholesterol transport, by which excess cholesterol is removed from peripheral tissues and returned to the liver for elimination (PubMed:17237796)",
                                "pubmed_ids": [
                                    "24293641",
                                    "3281933"
                                ]
                            }
                        ]
                    },
                    {
                        "symbol": "APOC3",
                        "description": "Apolipoprotein C3",
                        "category": "Protein Coding",
                        "protein_names": [
                            {
                                "protein_names": "Apolipoprotein C-III,Apolipoprotein C3",
                                "function": "Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma (PubMed:18201179, PubMed:22510806). Plays a multifaceted role in triglyceride homeostasis (PubMed:18201179, PubMed:22510806). Intracellularly, promotes hepatic very low density lipoprotein 1 (VLDL1) assembly and secretion; extracellularly, attenuates hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs) (PubMed:18201179, PubMed:22510806). Impairs the lipolysis of TRLs by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors (PubMed:18201179, PubMed:22510806). Formed of several curved helices connected via semiflexible hinges, so that it can wrap tightly around the curved micelle surface and easily adapt to the different diameters of its natural binding partners (PubMed:18408013)",
                                "pubmed_ids": [
                                    "18408013",
                                    "22510806"
                                ]
                            }
                        ]
                    },
                    {
                        "symbol": "LDLR",
                        "description": "Low Density Lipoprotein Receptor",
                        "category": "Protein Coding",
                        "protein_names": [
                            {
                                "protein_names": "Low-density lipoprotein receptor,",
                                "function": "Binds LDL, the major cholesterol-carrying lipoprotein of plasma, and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits\n(Microbial infection) Acts as a receptor for hepatitis C virus in hepatocytes, but not through a direct interaction with viral proteins\n(Microbial infection) Acts as a receptor for Vesicular stomatitis virus\n(Microbial infection) In case of HIV-1 infection, may function as a receptor for extracellular Tat in neurons, mediating its internalization in uninfected cells",
                                "pubmed_ids": [
                                    "3005267",
                                    "11100124"
                                ]
                            }
                        ]
                    },
                    {
                        "symbol": "APOA1-AS",
                        "description": "APOA1 Antisense RNA",
                        "category": "RNA Gene",
                        "protein_names": []
                    },
                    {
                        "symbol": "APOB",
                        "description": "Apolipoprotein B",
                        "category": "Protein Coding",
                        "protein_names": [
                            {
                                "protein_names": "Apolipoprotein B-100,",
                                "function": "Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor",
                                "pubmed_ids": []
                            }
                        ]
                    },
                    {
                        "symbol": "RORA",
                        "description": "RAR Related Orphan Receptor A",
                        "category": "Protein Coding",
                        "protein_names": [
                            {
                                "protein_names": "Nuclear receptor ROR-alpha,Nuclear receptor RZR-alpha,Nuclear receptor subfamily 1 group F member 1,RAR-related orphan receptor A,Retinoid-related orphan receptor-alpha",
                                "function": "Nuclear receptor that binds DNA as a monomer to ROR response elements (RORE) containing a single core motif half-site 5'-AGGTCA-3' preceded by a short A-T-rich sequence. Key regulator of embryonic development, cellular differentiation, immunity, circadian rhythm as well as lipid, steroid, xenobiotics and glucose metabolism. Considered to have intrinsic transcriptional activity, have some natural ligands like oxysterols that act as agonists (25-hydroxycholesterol) or inverse agonists (7-oxygenated sterols), enhancing or repressing the transcriptional activity, respectively. Recruits distinct combinations of cofactors to target genes regulatory regions to modulate their transcriptional expression, depending on the tissue, time and promoter contexts. Regulates genes involved in photoreceptor development including OPN1SW, OPN1SM and ARR3 and skeletal muscle development with MYOD1. Required for proper cerebellum development (PubMed:29656859). Regulates SHH gene expression, among others, to induce granule cells proliferation as well as expression of genes involved in calcium-mediated signal transduction. Regulates the circadian expression of several clock genes, including CLOCK, ARNTL/BMAL1, NPAS2 and CRY1. Competes with NR1D1 for binding to their shared DNA response element on some clock genes such as ARNTL/BMAL1, CRY1 and NR1D1 itself, resulting in NR1D1-mediated repression or RORA-mediated activation of clock genes expression, leading to the circadian pattern of clock genes expression. Therefore influences the period length and stability of the clock. Regulates genes involved in lipid metabolism such as apolipoproteins APOA1, APOA5, APOC3 and PPARG. In liver, has specific and redundant functions with RORC as positive or negative modulator of expression of genes encoding phase I and phase II proteins involved in the metabolism of lipids, steroids and xenobiotics, such as CYP7B1 and SULT2A1. Induces a rhythmic expression of some of these genes. In addition, interplays functionally with NR1H2 and NR1H3 for the regulation of genes involved in cholesterol metabolism. Also involved in the regulation of hepatic glucose metabolism through the modulation of G6PC1 and PCK1. In adipose tissue, plays a role as negative regulator of adipocyte differentiation, probably acting through dual mechanisms. May suppress CEBPB-dependent adipogenesis through direct interaction and PPARG-dependent adipogenesis through competition for DNA-binding. Downstream of IL6 and TGFB and synergistically with RORC isoform 2, is implicated in the lineage specification of uncommitted CD4(+) T-helper (T(H)) cells into T(H)17 cells, antagonizing the T(H)1 program. Probably regulates IL17 and IL17F expression on T(H) by binding to the essential enhancer conserved non-coding sequence 2 (CNS2) in the IL17-IL17F locus. Involved in hypoxia signaling by interacting with and activating the transcriptional activity of HIF1A. May inhibit cell growth in response to cellular stress. May exert an anti-inflammatory role by inducing CHUK expression and inhibiting NF-kappa-B signaling",
                                "pubmed_ids": [
                                    "10478845",
                                    "9862959"
                                ]
                            }
                        ]
                    },
                    {
                        "symbol": "SLC25A20",
                        "description": "Solute Carrier Family 25 Member 20",
                        "category": "Protein Coding",
                        "protein_names": [
                            {
                                "protein_names": "Mitochondrial carnitine/acylcarnitine carrier protein,Carnitine/acylcarnitine translocase,Solute carrier family 25 member 20",
                                "function": "Mediates the transport of acylcarnitines of different length across the mitochondrial inner membrane from the cytosol to the mitochondrial matrix for their oxidation by the mitochondrial fatty acid-oxidation pathway",
                                "pubmed_ids": []
                            }
                        ]
                    },
                    {
                        "symbol": "PPARA",
                        "description": "Peroxisome Proliferator Activated Receptor Alpha",
                        "category": "Protein Coding",
                        "protein_names": [
                            {
                                "protein_names": "Peroxisome proliferator-activated receptor alpha,Nuclear receptor subfamily 1 group C member 1",
                                "function": "Ligand-activated transcription factor. Key regulator of lipid metabolism. Activated by the endogenous ligand 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-GPC). Activated by oleylethanolamide, a naturally occurring lipid that regulates satiety. Receptor for peroxisome proliferators such as hypolipidemic drugs and fatty acids. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the ACOX1 and P450 genes. Transactivation activity requires heterodimerization with RXRA and is antagonized by NR2C2. May be required for the propagation of clock information to metabolic pathways regulated by PER2",
                                "pubmed_ids": [
                                    "10195690",
                                    "9556573"
                                ]
                            }
                        ]
                    }
                ],
                "genecards_pathways": [
                    {
                        "super_pathways": "Metabolism  66  Show member pathways   Metabolism of lipids 66",
                        "top_affiliating_genes": [
                            "ABCA1",
                            "LDLR"
                        ]
                    },
                    {
                        "super_pathways": "Transport of inorganic cations/anions and amino acids/oligopeptides  66  Show member pathways   Amino acid transport across the plasma membrane 66   Bicarbonate transporters 66   Cation-coupled Chloride cotransporters 66   Defective RHAG causes regulator type Rh-null hemolytic anemia (RHN) 66   Defective SLC12A1 causes Bartter syndrome 1 (BS1) 66   Defective SLC12A3 causes Gitelman syndrome (GS) 66   Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN) 66   Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT) 66   Defective SLC17A5 causes Salla disease (SD) and ISSD 66   Defective SLC17A8 causes autosomal dominant deafness 25 (DFNA25) 66   Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) 66   Defective SLC22A12 causes renal hypouricemia 1 (RHUC1) 66   Defective SLC22A18 causes lung cancer (LNCR) and embryonal rhabdomyosarcoma 1 (RMSE1) 66   Defective SLC22A5 causes systemic primary carnitine deficiency (CDSP) 66   Defective SLC24A4 causes hypomineralized amelogenesis imperfecta (AI) 66   Defective SLC24A5 causes oculocutaneous albinism 6 (OCA6) 66   Defective SLC26A3 causes congenital secretory chloride diarrhea 1 (DIAR1) 66   Defective SLC26A4 causes Pendred syndrome (PDS) 66   Defective SLC34A1 causes hypophosphatemic nephrolithiasis/osteoporosis 1 (NPHLOP1) 66   Defective SLC34A3 causes Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) 66   Defective SLC36A2 causes iminoglycinuria (IG) and hyperglycinuria (HG) 66   Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) 66   Defective SLC6A5 causes hyperekplexia 3 (HKPX3) 66   Defective SLC9A6 causes X-linked, syndromic mental retardation,, Christianson type (MRXSCH) 66   Defective SLC9A9 causes autism 16 (AUTS16) 66   Inositol transporters 66   Multifunctional anion exchangers 66   Na+/Cl- dependent neurotransmitter transporters 66   Organic anion transport 66   Organic anion transporters 66   Organic cation transport 66   Organic cation/anion/zwitterion transport 66   Proton/oligopeptide cotransporters 66   Proton-coupled monocarboxylate transport 66   Proton-coupled neutral amino acid transporters 66   Rhesus glycoproteins mediate ammonium transport. 66   SLC-mediated transmembrane transport 66   Sodium/Calcium exchangers 66   Sodium/Proton exchangers 66   Sodium-coupled phosphate cotransporters 66   Sodium-coupled sulphate, di- and tri-carboxylate transporters 66   Transport of bile salts and organic acids, metal ions and amine compounds 66   Transport of small molecules 66   Type II Na+/Pi cotransporters 66   Variant SLC6A14 may confer susceptibility towards obesity 66",
                        "top_affiliating_genes": [
                            "PLTP",
                            "CETP"
                        ]
                    },
                    {
                        "super_pathways": "Olfactory Signaling Pathway  66  Show member pathways   Expression and translocation of olfactory receptors 66   Sensory Perception 66",
                        "top_affiliating_genes": [
                            "LPL",
                            "APOA1"
                        ]
                    },
                    {
                        "super_pathways": "Nuclear receptors meta-pathway  74  Show member pathways   NRF2 pathway 74",
                        "top_affiliating_genes": [
                            "PPARA",
                            "APOA1"
                        ]
                    },
                    {
                        "super_pathways": "Metabolism of water-soluble vitamins and cofactors  66  Show member pathways   Biotin metabolism, including IMDs 74   Biotin transport and metabolism 66   Coenzyme A biosynthesis 66   Defective BTD causes biotidinase deficiency 66   Defective HLCS causes multiple carboxylase deficiency 66   Defects in biotin (Btn) metabolism 66   Metabolism of folate and pterines 66   Metabolism of vitamins and cofactors 66   molybdenum cofactor biosynthesis 61   Molybdenum cofactor biosynthesis 66   thiamin salvage III 61   Vitamin B1 (thiamin) metabolism 66   Vitamin B2 (riboflavin) metabolism 66   Vitamin B5 (pantothenate) metabolism 66   Vitamin C (ascorbate) metabolism 66   Vitamins B6 activation to pyridoxal phosphate 66",
                        "top_affiliating_genes": [
                            "LPL",
                            "APOA1"
                        ]
                    },
                    {
                        "super_pathways": "Visual phototransduction  66  Show member pathways   Activation of the phototransduction cascade 66   Defective SLC24A1 causes congenital stationary night blindness 1D (CSNB1D) 66   Inactivation, recovery and regulation of the phototransduction cascade 66   menaquinol-4 biosynthesis II 61   Metabolism of fat-soluble vitamins 66   Metabolism of vitamin K 66   Retinoid metabolism and transport 66   retinol biosynthesis 61   The phototransduction cascade 66   The retinoid cycle in cones (daylight vision) 66   the visual cycle I (vertebrates) 61   Visual signal transduction: Rods 61   Vitamin E 66",
                        "top_affiliating_genes": [
                            "LPL",
                            "APOA1"
                        ]
                    },
                    {
                        "super_pathways": "PPARA activates gene expression  66  Show member pathways   Regulation of lipid metabolism by PPARalpha 66   Transcriptional regulation of white adipocyte differentiation 66",
                        "top_affiliating_genes": [
                            "ABCA1",
                            "RORA"
                        ]
                    },
                    {
                        "super_pathways": "Plasma lipoprotein assembly, remodeling, and clearance  66  Show member pathways   Assembly of active LPL and LIPC lipase complexes 66   Chylomicron assembly 66   Chylomicron clearance 66   Chylomicron remodeling 66   Defective ABCA1 causes TGD 66   HDL assembly 66   HDL clearance 66   HDL remodeling 66   LDL clearance 66   LDL remodeling 66   Metabolic pathway of LDL, HDL and TG, including diseases 74   Plasma lipoprotein assembly 66   Plasma lipoprotein clearance 66   Plasma lipoprotein remodeling 66   VLDL assembly 66   VLDL clearance 66   VLDLR internalisation and degradation 66",
                        "top_affiliating_genes": [
                            "ABCA1",
                            "CETP"
                        ]
                    },
                    {
                        "super_pathways": "Circadian Clock  66  Show member pathways   BMAL1:CLOCK,NPAS2 activates circadian gene expression 66   Circadian Clock in Mammals 64   Heme signaling 66   NR1D1 (REV-ERBA) represses gene expression 66   RORA activates gene expression 66",
                        "top_affiliating_genes": [
                            "RORA",
                            "APOA1"
                        ]
                    },
                    {
                        "super_pathways": "Adipogenesis  74",
                        "top_affiliating_genes": [
                            "RORA",
                            "LPL"
                        ]
                    },
                    {
                        "super_pathways": "NR1H2 and NR1H3-mediated signaling  66  Show member pathways   NR1H2 and NR1H3 regulate gene expression linked to gluconeogenesis 66   NR1H2 and NR1H3 regulate gene expression linked to lipogenesis 66   NR1H2 and NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose 66   NR1H2 and NR1H3 regulate gene expression to control bile acid homeostasis 66   NR1H2 and NR1H3 regulate gene expression to limit cholesterol uptake 66   NR1H3 and NR1H2 regulate gene expression linked to cholesterol transport and efflux 66",
                        "top_affiliating_genes": [
                            "PLTP",
                            "ABCA1"
                        ]
                    },
                    {
                        "super_pathways": "PPAR signaling pathway  74  Show member pathways   FABP4 in ovarian cancer 74   Fatty acid transporters 74",
                        "top_affiliating_genes": [
                            "PPARA",
                            "APOA1"
                        ]
                    },
                    {
                        "super_pathways": "Statin inhibition of cholesterol production  74  Show member pathways   Familial hyperlipidemia type 3 74   Lipid particles composition 74   Statin Pathway, Pharmacodynamics 60",
                        "top_affiliating_genes": [
                            "ABCA1",
                            "CETP"
                        ]
                    },
                    {
                        "super_pathways": "Fatty acid beta-oxidation  74  Show member pathways   mitochondrial fatty acid beta-oxidation of unsaturated fatty acids 66",
                        "top_affiliating_genes": [
                            "SLC25A20",
                            "LPL",
                            "LIPC"
                        ]
                    },
                    {
                        "super_pathways": "Familial hyperlipidemia type 1  74  Show member pathways   Familial hyperlipidemia type 2 74   Familial hyperlipidemia type 4 74   Familial hyperlipidemia type 5 74",
                        "top_affiliating_genes": [
                            "APOA1",
                            "LDLR"
                        ]
                    },
                    {
                        "super_pathways": "PPAR-alpha pathway  74",
                        "top_affiliating_genes": [
                            "PPARA",
                            "APOA1"
                        ]
                    },
                    {
                        "super_pathways": "Familial partial lipodystrophy  74",
                        "top_affiliating_genes": [
                            "PPARA",
                            "LPL"
                        ]
                    },
                    {
                        "super_pathways": "Cholesterol and Sphingolipids transport / Transport from Golgi and ER to the apical membrane (normal and CF) 22",
                        "top_affiliating_genes": [
                            "CETP",
                            "ABCA1"
                        ]
                    },
                    {
                        "super_pathways": "Cholesterol and Sphingolipids transport / Recycling to plasma membrane in lung (normal and CF) 22",
                        "top_affiliating_genes": [
                            "APOA2",
                            "ABCA1"
                        ]
                    },
                    {
                        "super_pathways": "SREBF and miR33 in cholesterol and lipid homeostasis  74",
                        "top_affiliating_genes": [
                            "PPARA",
                            "ABCA1"
                        ]
                    }
                ],
                "related_symptoms": [],
                "summary_table_incidence": [],
                "summary_table_prevalence": [],
                "summary_table_other": [],
                "pubmed_treatment": "",
                "pubmed_treatment_cn": "",
                "cancer_treatment": [],
                "drugs": [],
                "ddx": []
            }
        ],
        "total": 2137
    },
    "message": ""
}

临床试验注册信息（美国）数据库

/pharma/demo/v1/clinical_registration_usa/list

*样例数据限制条件：first_posted（登记日期）=2024-01-01至2024-02-29

curl --location --request POST 'https://srv-openapi.bcpmdata.com/pharma/demo/v1/clinical_registration_usa/list' \
--header 'Content-Type: application/json' \
--header 'Authorization: Bearer 你的token' \
--data-raw '{
    "page": 1,
    "page_size": 10,
    "search": {
        "all": "NCT06287164",
        "registration_number": "NCT06287164",
        "registration_number_1_json": [
            "101"
        ],
        "title": "Management",
        "phase_json_cn": "临床阶段不明",
        "country_territory_json_cn": "意大利",
        "first_posted": {
            "min": "2024-01-01",
            "max": "2024-02-29"
        }
    }
}'

{
    "code": 10200,
    "data": {
        "list": [
            {
                "registration_number": "NCT05917483",
                "registration_url": "https://clinicaltrials.gov/study/NCT05917483?rank=1",
                "first_posted": "2023-06-23",
                "registration_number_1_json": [
                    "NTUH-REC 201812022RINC",
                    "NCT05917392"
                ],
                "title": "Evaluation of Mechanical Characteristics of Tendons of Athletes Using Sonography",
                "scientific_title": "Evaluation of Mechanical Characteristics and Prevention From Overuse Injury of Tendons of Elite Athletes Using Dynamic Sonography",
                "country_territory_json": [
                    {
                        "cn": "中国台湾",
                        "en": "Taiwan"
                    }
                ],
                "manufacturer_json": [
                    {
                        "cn": "辰欣佛都药业(汶上)有限公司",
                        "en": "National Taiwan University Hospital"
                    }
                ],
                "company_json": [],
                "linked_study_record": [],
                "start_date": "2021-01-14",
                "primary_completion_date": "2022-03-02",
                "end_date": "2022-03-02",
                "result_date": "",
                "last_change_date": "2023-06-23",
                "recruitment_status_json": {
                    "cn": "完成招募",
                    "en": "Completed"
                },
                "registration_authority": "美国",
                "drug_name_json": [
                    {
                        "cn": "盐酸安普乐定",
                        "en": "Ultrasonography"
                    }
                ],
                "drug_category": [
                    "抗过敏药",
                    "止吐药"
                ],
                "intervention_info": [
                    {
                        "name": "Ultrasonography",
                        "type": "诊断"
                    }
                ],
                "target_json": [],
                "target_role": [],
                "technologies_json": [],
                "indication_json": [
                    {
                        "cn": "",
                        "en": "Overuse Injury"
                    },
                    {
                        "cn": "",
                        "en": "Rotator Cuff Injuries"
                    }
                ],
                "active_indications_json": [],
                "indication_area": [
                    "损伤、中毒、职业病"
                ],
                "phase_json": [
                    {
                        "cn": "临床阶段不明",
                        "en": "Phase Not Applicable"
                    }
                ],
                "study_type_json": [
                    {
                        "cn": "观察性研究",
                        "en": "Observational"
                    }
                ],
                "primary_purpose_json": [],
                "category_json": [
                    {
                        "cn": "诊断",
                        "en": "Diagnostic"
                    }
                ],
                "allocation": "",
                "intervention_model": "",
                "masking": "",
                "blinded": "",
                "observation_model": "其他",
                "observational_perspective": "前瞻性",
                "patient_registry": "否",
                "follow_up_time": "",
                "biospecimen_retention": "",
                "biospecimen_description": "",
                "regimens_us": [],
                "biomarker": "",
                "biomarker_type_1": "",
                "biomarker_role": "",
                "endpoint_types_json": [],
                "primary_endpoints": [
                    {
                        "endpoint": "Peak tendon strain",
                        "timepoint": "Two months",
                        "description": "The peak value of tendon strain during the isotonic motion estimated from ultrasound image sequence"
                    }
                ],
                "secondary_endpoints": [],
                "other_endpoints": [],
                "reference_json": [],
                "first_enrollment_date": "",
                "anticipated_enrollment_count": "",
                "actual_enrollment_count": "10",
                "age_range": "21 Years - 33 Years",
                "gender": "Male",
                "accepts_healthy_volunteers": "Yes",
                "enrollment_period": "",
                "enrollment_rate": "",
                "inclusion_and_exclusion_criteria": "<div class=\"clinic_criteria\"><p>Inclusion Criteria:</p><ul><li>Baseball pitchers in city baseball team</li></ul><p>Exclusion Criteria:</p><ul><li>History of shoulder disorder or surgery</li></ul></div>",
                "contact_json": [],
                "site_json": [
                    "Tianmu Sports Park/ Baseball Stadium"
                ],
                "publications_results": "否",
                "result_json": [],
                "documents_json": []
            }
        ],
        "total": 1
    },
    "message": ""
}

常规词典数据库

/pharma/demo/v1/common_dictionary/list****

*样例数据限制条件：内部数据ID小于等于5000

curl --location --request POST 'https://srv-openapi.bcpmdata.com/pharma/demo/v1/common_dictionary/list' \
--header 'Content-Type: application/json' \
--header 'Authorization: Bearer 你的token' \
--data '{
    "search": {
        "en": "Infections",
        "cn": "先天性感染及侵染疾病",
        "alias": "先天性感染及侵染疾病",
        "type": "disease"
    },
    "page": 1,
    "page_size": 10
}'

{
    "code": 10200,
    "data": {
        "list": [
            {
                  "en": "Non-small cell lung cancer",
                  "cn": "非小细胞肺癌",
                  "alias": [
                      "癌, 非小细胞肺",
                      "非小细胞肺癌易感性",
                      "NSCLC"
                  ],
                  "type": "disease"
            }
        ],
        "total": 7
    },
    "message": ""
}

商品名关系词典数据库

/pharma/demo/v1/trade_name_dictionary/list

*样例数据限制条件：内部数据ID小于等于3000

curl --location --request POST 'https://srv-openapi.bcpmdata.com/pharma/demo/v1/trade_name_dictionary/list' \
--header 'Content-Type: application/json' \
--header 'Authorization: Bearer 你的token' \
--data '{
    "search": {
        "all": "INDERAL",
        "active_ingredient": "HYDROCHLORIDE",
        "company": "AstraZeneca",
        "trade_name": "INDERAL"
    },
    "page": 1,
    "page_size": 10
}'

{
    "code": 10200,
    "data": {
        "list": [
             {
                "active_ingredient": [
                    "PROPRANOLOL HYDROCHLORIDE",
                    "盐酸普萘洛尔"
                ],
                "company": [
                    "阿斯特拉（无锡）制药有限公司",
                    "AstraZeneca KK",
                    "WYETH PHARMS",
                    "WYETH AYERST",
                    "Astrazeneca Pharmaceutical Co.,Ltd.",
                    "AKRIMAX PHARMS",
                    "阿斯利康制药有限公司",
                    "日本太阳化学株式会社"
                ],
                "trade_name": [
                    "INDERAL"
                ]
            }
        ],
        "total": 2137
    },
    "message": ""
}